Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
Open Access
- 30 March 2011
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (4), 867-870
- https://doi.org/10.1002/art.30207
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Venous and arterial thromboembolic events in adalimumab‐treated patients with antiadalimumab antibodies: A case series and cohort studyArthritis & Rheumatism, 2011
- Bronchospasm associated with anti-TNF treatmentClinical Rheumatology, 2009
- Arterial and venous thromboembolic events during anti-TNF therapy: A study of 85 spontaneous reports in the period 2000–2006Bio-Medical Materials and Engineering, 2009
- Clinical immunotoxicity of therapeutic proteinsExpert Opinion on Drug Metabolism & Toxicology, 2008
- Case Study: Immunogenicity of Anti-TNF AntibodiesPublished by Springer Science and Business Media LLC ,2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Biologic therapies in rheumatology: lessons learned, future directionsNature Reviews Drug Discovery, 2007
- Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximabArthritis & Rheumatism, 2006
- Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2005